Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 28;17(1):782.
doi: 10.1186/s12913-017-2750-x.

The development, implementation and evaluation of clinical pathways for chronic obstructive pulmonary disease (COPD) in Saskatchewan: protocol for an interrupted times series evaluation

Thomas Rotter  1   2 , Christopher Plishka  3 , Mohammed Rashaad Hansia  4 , Donna Goodridge  5   6 , Erika Penz  5 , Leigh Kinsman  7 , Adegboyega Lawal  1 , Sheryl O'Quinn  4 , Nancy Buchan  4 , Patricia Comfort  4 , Prakesh Patel  4 , Sheila Anderson  4 , Tanya Winkel  4 , Rae Lynn Lang  4 , Darcy D Marciniuk  5   6
Affiliations

The development, implementation and evaluation of clinical pathways for chronic obstructive pulmonary disease (COPD) in Saskatchewan: protocol for an interrupted times series evaluation

Thomas Rotter et al. BMC Health Serv Res. .

Abstract

Background: Chronic obstructive pulmonary disease (COPD) has substantial economic and human costs; it is expected to be the third leading cause of death worldwide by 2030. To minimize these costs high quality guidelines have been developed. However, guidelines alone rarely result in meaningful change. One method of integrating guidelines into practice is the use of clinical pathways (CPWs). CPWs bring available evidence to a range of healthcare professionals by detailing the essential steps in care and adapting guidelines to the local context.

Methods/design: We are working with local stakeholders to develop CPWs for COPD with the aims of improving care while reducing utilization. The CPWs will employ several steps including: standardizing diagnostic training, unifying components of chronic disease care, coordinating education and reconditioning programs, and ensuring care uses best practices. Further, we have worked to identify evidence-informed implementation strategies which will be tailored to the local context. We will conduct a three-year research project using an interrupted time series (ITS) design in the form of a multiple baseline approach with control groups. The CPW will be implemented in two health regions (experimental groups) and two health regions will act as controls (control groups). The experimental and control groups will each contain an urban and rural health region. Primary outcomes for the study will be quality of care operationalized using hospital readmission rates and emergency department (ED) presentation rates. Secondary outcomes will be healthcare utilization and guideline adherence, operationalized using hospital admission rates, hospital length of stay and general practitioner (GP) visits. Results will be analyzed using segmented regression analysis.

Discussion: Funding has been procured from multiple stakeholders. The project has been deemed exempt from ethics review as it is a quality improvement project. Intervention implementation is expected to begin in summer of 2017. This project is expected to improve quality of care and reduce healthcare utilization. In addition it will provide evidence on the effects of CPWs in both urban and rural settings. If the CPWs are found effective we will work with all stakeholders to implement similar CPWs in surrounding health regions.

Trial registration: Clinicaltrials.gov ( NCT03075709 ). Registered 8 March 2017.

Keywords: COPD; Care maps; Care pathways; Chronic obstructive pulmonary disease; Clinical pathways; Critical pathways; Integrated care pathways.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The Research Ethics Board deemed to the project to be exempt from ethics review as the work conducted is a quality improvement project using automatically collected and de-identified data.

Consent for publication

Not applicable.

Competing interests

This research is supported by Novartis Pharmaceuticals Canada Inc.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. O'Donnell DE, Hernandez P, Rocker G, Kaplan A, Aaron S, Voduc N, Bourbeau J, Marciniuk D, Balter M, Ford G, et al. Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J. 2008;15:1A. doi: 10.1155/2008/973062. - DOI - PMC - PubMed
    1. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG, et al. Prevention of acute exacerbation of COPD: American college of chest physicians and Canadian thoracic society guideline.(chronic obstructive lung disease)(report) Chest. 2015;147(4):883. doi: 10.1378/chest.14-1677. - DOI - PMC - PubMed
    1. Grimshaw JM, Schünemann HJ, Burgers J, Cruz AA, Heffner J, Metersky M, Cook D. Disseminating and implementing guidelines: article 13 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report In. 2012;9:298–303. - PubMed
    1. Marciniuk DD, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, Ford G, Bourbeau J, O'Donnell D, Maltais F, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian thoracic society clinical practice guideline. Can Respir J. 2011;18(2):69–78. doi: 10.1155/2011/745047. - DOI - PMC - PubMed
    1. Mannino DM. COPD: epidemiology, prevalence, morbidity and morality, and disease heterogeneity.(chronic obstructive pulmonary disease) Chest. 2002;121(5):121S. doi: 10.1378/chest.121.5_suppl.121S. - DOI - PubMed

MeSH terms

Associated data